A Phase 3, Open label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13 [EXTENSTION OF 700033114]

Trial Profile

A Phase 3, Open label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13 [EXTENSTION OF 700033114]

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; MMR-varicella zoster virus vaccine
  • Indications Chickenpox; Measles; Meningococcal group B infections; Mumps; Rubella
  • Focus Pharmacodynamics; Registrational
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 12 Apr 2016 Results (pooled analysis of this and other three studies) assessing whether pooled-sera hSBA titres predict individual seroprotection published in the Vaccine.
    • 05 Mar 2015 New source identified and integrated (ClinicalTrials.gov record: NCT00847145)
    • 21 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top